Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-10-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines for serious diseases, led by CASGEVY and a pipeline spanning cardiovascular, autoimmune, oncology and diabetes programs.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From first approval to broader franchise proof
One approval has removed the science-fiction discount, but it has not yet created a durable commercial franchise. The next five years hinge on whether access friction eases and at least one wholly owned program graduates from promise to credible launch visibility.

Analysis

Thesis
CRISPR Therapeutics has enough cash, platform breadth and first-product credibility to turn a landmark approval into a broader gene-editing franchise; if CASGEVY becomes a durable commercial anchor and at least one wholly owned follow-on asset proves launch-worthy, the stock can compound well above market norms without needing every pipeline branch to work.
Last Economy Alignment
AI helps design and portfolio iteration, but CRISPR captures value through regulated biology, IP, manufacturing and clinical trust rather than software seats. That is positive, though proof, access and reimbursement remain the real bottlenecks.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The upside is a re-rating from single-product validation to multi-franchise credibility. CASGEVY should become a steadier commercial anchor, while one cardiovascular and one autoimmune program can move close enough to registration to justify a higher revenue multiple. The cap is that shared economics, site activation and early clinical risk should limit how far investors underwrite 2031 value today.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not survival. CRISPR must show that CASGEVY approvals translate into treated patients and that at least one wholly owned follow-on program survives safety, durability and manufacturability scrutiny. If those gates slip, the market is likely to keep valuing the company as cash plus scientific optionality rather than as a compounding multi-franchise biotech.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.33
They do not sell software that AI can copy; they sell regulated therapies built on editing know-how, manufacturing and clinical trust. AI can speed discovery, but the real bottlenecks are proving safety, getting reimbursed and moving patients through treatment centers.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case